STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Tharimmune Insider Shows Confidence with Major Stock Purchase at $1.48

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Gravitas Capital LP, a significant insider at Tharimmune (THAR), has reported a substantial purchase of company shares. On June 20, 2025, the entity acquired 337,838 shares of Common Stock at a price of $1.48 per share, representing a total investment of approximately $500,000.

Following this transaction, Gravitas Capital LP now owns 732,424 shares directly. The reporting person holds multiple positions within the company, serving as:

  • Executive Chairman
  • Director
  • 10% Owner

This insider purchase by a high-ranking executive and major shareholder could signal confidence in the company's future prospects. The transaction was reported within the required filing deadline, with the Form 4 being signed by Vincent LoPriore on June 23, 2025.

Positive

  • Executive Chairman and 10% owner Gravitas Capital LP purchased 337,838 shares at $1.48 per share for approximately $500,000, demonstrating significant insider confidence through open market purchase

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gravitas Capital LP

(Last) (First) (Middle)
C/O THARIMMUNE, INC.
34 SHREWSBURY AVENUE

(Street)
RED BANK NJ 07701

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tharimmune, Inc. [ THAR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Executive Chairman
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 P 337,838 A $1.48 732,424 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Vincent LoPriore 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of THAR stock did Gravitas Capital LP purchase on June 20, 2025?

According to the Form 4 filing, Gravitas Capital LP purchased 337,838 shares of THAR common stock at a price of $1.48 per share on June 20, 2025.

What is Gravitas Capital LP's total position in THAR stock after their June 2025 purchase?

Following the reported transaction, Gravitas Capital LP directly owns 732,424 shares of THAR common stock.

What positions does Gravitas Capital LP hold at THAR?

Gravitas Capital LP holds multiple positions at THAR, serving as a Director, 10% Owner, and Executive Chairman of the company.

What was the purchase price per share for THAR stock in Gravitas Capital's June 2025 transaction?

Gravitas Capital LP purchased THAR shares at a price of $1.48 per share.

When was the Form 4 for THAR insider trading filed relative to the transaction date?

The Form 4 was filed on June 28, 2025, which was 8 days after the transaction date of June 20, 2025. The form was signed by Vincent LoPriore on June 23, 2025.
Tharimmune Inc

NASDAQ:THAR

THAR Rankings

THAR Latest News

THAR Latest SEC Filings

THAR Stock Data

89.71M
32.47M
17.13%
1.5%
12.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER